Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

Molecular Interventions

Volumn 9, Issue 2, 2009, Pages 75-78

  Pollock, David M ^a   Boesen, Erika I ^a   Black, Stephen M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 132577; BOSENTAN; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO VALYLLEUCYL DEXTRO TRYPTOPHYL); ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; MACITENTAN; SITAXSENTAN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; DRUG EFFECT; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ENDOTHELIN-1; HUMANS; PROTEIN BINDING; RECEPTORS, ENDOTHELIN;

EID: 65949120920     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.2.6     Document Type: Review

References (33)

1. Ohnaka, K., Takayanagi, R., Nishikawa, M., Haji, M., and Nawata, H. Purification and characterization of a phosphoramidon-sensitive endothe- lin-converting enzyme in porcine aortic endothelium. J. Biol. Chem. 268, 26759-26766 (1993).
2. Chiou W.J., Shiosaki, K., Tasker, A.S., and Wu-Wong, J.R. Characterization of two endothelin converting enzymes and their preference for big endothelin-1 and -2 as substrates. Life Sci. 54, 1613-1619 (1994).
3. Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D., and Yanagisawa, M. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78, 473-485 (1994).
4. Luscher, T.F., Yang, Z., Tschudi, M., von Segesser, L., Stulz, P., Boulanger, C., Siebenmann, R., Turina, M., and Buhler, F.R. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ. Res. 66, 1088-1094 (1990).
5. Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., and Masaki, T. Cloning of a cDNA encoding a non-isopeptide-selec- tive subtype of the endothelin receptor. Nature 348, 732-735 (1990).
6. Arai, H., Nakao, K., Takaya, K., Hosoda, K., Ogawa, Y., Nakanishi, S., and Imura, H. The human endothelin-B receptor gene. Structural organization and chromosomal assignment. J. Biol. Chem. 268, 3463-3470 (1993).
7. Schneider, M.P., Boesen, E.I., and Pollock, D.M. Contrasting actions of endothelin ETA and ETB receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 47, 731-759 (2007). A fairly recent and thorough review of endothelin receptor specific actions in physiology and disease focusing on receptor specific actions.
8. Ito, H., Hirata, Y., Hiroe, M., Tsujino, M., Adachi, S., Takamoto, T., Nitta, M., Taniguchi, K., and Marumo, F. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ. Res. 69, 209-215 (1991).
9. Kahaleh, M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 34, 978-983 (1991).
10. Xu, S.W., Denton, C.P., Dashwood, M.R., Abraham, D.J., and Black, C.M. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J. Cardiovasc. Pharmacol. 31 (Suppl 1), S545-S547 (1998).
11. Filep, J.G., Fournier, A. and Foldes-Filep, E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: Involvement of ETA and ETB receptors. Br. J. Pharmacol. 115, 227-236 (1995).
12. Nootens, M., Kaufmann, E., Rector, T., Toher, C., Judd, D., Francis, G.S., and Rich, S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J. Am. Coll. Cardiol. 26, 1581-1585 (1995).
13. Rubens, C., Ewert, R., Halank, M., Wensel, R., Orzechowski, H.D., Schultheiss, H.P., and Hoeffken, G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120, 1562-1569 (2001).
14. Opitz, C.F., Ewert, R., Kirch, W., and Pittrow, D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: Does selectivity matter? Eur. Heart J. 29, 1936-1948 (2008).
15. Fabregat, I. and Rozengurt, E. [D-Arg1,D-Phe5,D-Trp7,9,Leu11] substance P, a neuropeptide antagonist, blocks binding, Ca2+-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells. J. Cell Physiol. 145, 88-94 (1990).
16. Ihara, M., Noguchi, K., Saeki, T. et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50, 247-255 (1992). Study describing the discovery and origins of the first widely used endothelin receptor antagonists.
17. Rubin, L.J. and Roux, S. Bosentan: A dual endothelin receptor antagonist. Expert Opin. Investig. Drugs 11, 991-1002 (2002). A review of the discovery and utility of bosentan, the first endothelin antagonist approved for use in humans.
18. Barst, R.J., Langleben, D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169, 441-447 (2004).
19. Galie, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M.L., and Branzi, A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30, 394-403 (2009). A recent review that places endothelin antagonists in context with other clinical trials in the treatment of pulmonary hypertension.
20. Clozel, M., Breu, V., Gray, G.A. et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270, 228-235 (1994). Pharmacology of the first orally active, commerially available endothelin receptor antagonist.
21. Hirata, Y., Emori, T., Eguchi, S., Kanno, K., Imai, T., Ohta, K., and Marumo, F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. 91, 1367-1373 (1993).
22. Black, S.M., Mata-Greenwood, E., Dettman, R.W. et al. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation 108, 1646-1654 (2003).
23. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., and Kohan, D.E. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., and Kohan, D.E. Profile of past and current clinical trials involving endothelin receptor antagonists: The novel "-sentan" class of drug. Exp. Biol. Med. (Maywood) 231, 653-695 (2006). A comprehensive review of clinical trials involving endothelin receptor antagnists and includes excellent summaries of receptor selectivity, pharmacokinetics, common adverse effects, success or failure to achieve therapeutic benefit in the targeted diseases and outcomes of selective preclinical studies in animals.
24. Iglarz, M., Binkert, C., Morrison, K., Fischli W., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736-745 (2008). Report of the first endothelin receptor antagonist designed to target lipophilic environments.
25. Nakamura, K., Sasaki, S., Moriguchi, J., Morimoto, S., et al. Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. J. Cardiovasc. Pharmacol. 33, 876-882 (1999).
26. Gupta, Y.K., Briyal, S., Sharma, U., Jagannathan, N.R., and Gulati, A. Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci. 77, 15-27 (2005).
27. Zhang, W.W., Badonic, T., Hoog, A., Jiang, M.H., Jiang, M.H., Ma, K.C., Nie, X.J., and Olsson, Y. Astrocytes in Alzheimer's disease express immunoreactivity to the vaso-constrictor endothelin-1. J. Neurol. Sci. 122, 90-96 (1994).
28. Rolinski, B., Heigermoser, A., Lederer, E., Bogner, J.R., Loch, O., and Goebel, F.D. Endothelin-1 is elevated in the cerebrospinal fluid of HIV- infected patients with encephalopathy. Infection 27, 244-247 (1999).
29. Pollock, D.M. and Pollock, J.S. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol. Renal Physiol. 281, F144-F150 (2001).
30. Ge, Y., Bagnall, A., Stricklett, P. K., Strait, K., Webb, D.J., Kotelevtsev, Y., and Kohan D.E. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am. J. Physiol. Renal Physiol. 291, F1274-F1280 (2006). Convincing evidence that ETB receptors within the kidney play a critical role in preventing salt-dependent hypertension.
31. Nishida, M., Eshiro, K., Okada, Y., Takaoka, M., and Matsumura, Y. Roles of endothelin ETA and ETB receptors in the pathogenesis of monocro- taline-induced pulmonary hypertension. J. Cardiovasc. Pharmacol. 44, 187-191 (2004).
32. Jasmin, J.F., Lucas, M., Cernacek, P. and Dupuis, J. Effectiveness of a nonselective ETA/B and a selective ETA antagonist in rats with monocrota- line-induced pulmonary hypertension. Circulation 103, 314-318 (2001).
33. Pfab, T., Thone-Reineke, C., Theilig, F. et al. Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J. Am. Soc. Nephrol. 17, 1082-1089 (2006).